The Potential of Umbilical Cord–Derived Mesenchymal Stem Cells in Rheumatoid Arthritis of the Hand Joints
Treatments By body area Knee & joints Spine, neck & back Hip Shoulder By condition Autoimmune & inflammatory Neurological Diabetes Anti-aging & vitality Every treatment uses the same Passage 3 protocol. View all treatments How it works Your journey Testimonials Pricing About The center The company The stem cells Facilities People & place Dr. Diana Reyes The team About Medellín ENES Book your consultation Message us Treatments + By body area Knee & joints Spine, neck & back Hip Shoulder By condition Autoimmune & inflammatory Neurological Diabetes Anti-aging & vitality View all treatments → How it works Your journey Testimonials Pricing About + The company The stem cells Dr. Diana Reyes The team Facilities About Medellín ENES Book your consultation Message us on WhatsApp Regenerative science The Potential of Umbilical Cord–Derived Mesenchymal Stem Cells in Rheumatoid Arthritis of the Hand Joints Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, and… By Dr. Diana ReyesFebruary 2026 Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, and functional disability. The small joints of the hands are among the most commonly and severely affected, leading to pain, stiffness, deformity, and loss of fine motor function that significantly impacts daily living. Although conventional disease-modifying antirheumatic drugs (DMARDs), biologic agents, and corticosteroids have transformed RA management, many patients continue to experience disease progression, medication-related adverse effects, or inadequate symptom control. In this context, regenerative medicine—particularly therapies based on umbilical cord–derived mesenchymal stem cells (UC-MSCs)—has emerged as a promising biologic strategy targeting the immune and inflammatory drivers of RA. Pathophysiology of Rheumatoid Arthritis in the Hand Joints Rheumatoid arthritis is driven by an aberrant immune response that targets synovial tissue, resulting in chronic inflammation and progressive joint damage. In the hand joints, this process leads to synovial hypertrophy (pannus formation), cartilage degradation, and bone erosion. Key pathological mechanisms include: McInnes and Schett (2011) describe RA as a disease in which immune-mediated inflammation and tissue destruction are tightly linked, particularly in small synovial joints such as those of the hands. Why Umbilical Cord–Derived Mesenchymal Stem Cells? Umbilical cord–derived mesenchymal stem cells, most commonly isolated from Wharton’s jelly, possess unique immunomodulatory and anti-inflammatory properties that make them particularly attractive for autoimmune and inflammatory diseases such as RA. UC-MSCs are known to: El Omar et al. (2014) emphasize that perinatal MSCs demonstrate stronger immunomodulatory effects than adult-derived MSCs, making them well suited for immune-mediated disorders. Mechanisms of Action in Rheumatoid Arthritis The therapeutic effects of UC-MSCs in RA are primarily mediated through paracrine and immunoregulatory mechanisms rather than direct tissue replacement. These mechanisms include: Caplan and Correa (2011) describe MSCs as a “biologic drugstore,” highlighting their ability to secrete bioactive factors that orchestrate immune balance and tissue protection. Clinical Applications in Hand Joint Rheumatoid Arthritis UC-MSC–based therapies are being explored as adjunctive or alternative treatments for patients with RA who have persistent hand joint symptoms despite standard medical therapy. Intra-Articular and Periarticular UC-MSC Injection Targeted, image-guided injection of UC-MSCs into affected hand joints aims to reduce synovial inflammation, alleviate pain, and improve joint function. Early clinical studies of MSC therapy in RA have demonstrated reductions in disease activity scores and inflammatory markers. Wang et al. (2013) reported that MSC therapy in patients with active RA led to significant improvements in clinical symptoms and inflammatory indices without serious adverse events. Systemic Immunomodulatory Effects Beyond local joint treatment, UC-MSCs may exert systemic immune-regulating effects, potentially reducing overall disease activity and slowing progression when used as part of a comprehensive RA management strategy. Evidence from Reviews and Clinical Studies Safety“Umbilical cord–derived mesenchymal stem cells show excellent safety and tolerability in patients with autoimmune diseases, including rheumatoid arthritis.”— Wang et al., 2021 Immunomodulatory Effects“MSCs effectively suppress inflammatory immune responses and restore immune tolerance in rheumatoid arthritis.”— Djouad et al., 2009 Clinical Outcomes“MSC therapy significantly reduced disease activity and improved functional outcomes in patients with refractory RA.”— Wang et al., 2013 Conclusion Rheumatoid arthritis of the hand joints is a debilitating condition driven by chronic immune-mediated inflammation, leading to progressive joint damage and functional loss. Umbilical cord–derived mesenchymal stem cells represent a biologically targeted therapeutic approach that addresses the underlying immune dysregulation rather than focusing solely on symptom control. Current evidence suggests that UC-MSC–based therapies offer: As regenerative medicine continues to advance, UC-MSC therapy holds significant promise as a complementary strategy in the management of rheumatoid arthritis affecting the hand joints. References Talk to our medical team ← Keep reading Welcome to Medellín Your treatment can start this week. No months-long waitlist. Message us and a real person — Mía — will get back to you in minutes. Message us on WhatsApp Book your consultation A leading center in regenerative medicine, dedicated to pain relief and health you can feel. Explore Treatments How it works Testimonials Pricing Blog FAQs Book Company About Dr. Diana Reyes The team Facilities About Medellín Contact WhatsApp +57 310 881 9333 info@stemcellscolombia.com Incodol Sede Balsos, Carrera 25 #9A Sur-162, Consultorio #3, El Poblado, Medellín Mon–Fri 10am–6pm · Sat 10am–2pm (GMT-5) Medical disclaimer. Stem cell therapy does not guarantee results and is not marketed as a definitive cure. A comprehensive review of each patient’s medical history is required to assess eligibility. Individual results vary; these therapies are not approved by the FDA and are not a substitute for conventional medical care. Any personal information shared is used solely within our medical team. © 2026 Stemcells Colombia. All rights reserved. Terms Privacy SMS Policy Chat with us